144 related articles for article (PubMed ID: 36519119)
21. Fecal Microbiota Transplant in Severe and Non-Severe
Popa D; Neamtu B; Mihalache M; Boicean A; Banciu A; Banciu DD; Moga DFC; Birlutiu V
J Clin Med; 2021 Dec; 10(24):. PubMed ID: 34945118
[TBL] [Abstract][Full Text] [Related]
22. Impact of Updated Clinical Practice Guidelines on Outpatient Treatment for
Dubberke ER; Puckett JT; Obi EN; Kamal-Bahl S; Desai K; Stuart B; Doshi JA
Open Forum Infect Dis; 2022 Oct; 9(10):ofac435. PubMed ID: 36267250
[TBL] [Abstract][Full Text] [Related]
23. Clostridioides difficile infection in immunocompromised hospitalized patients is associated with a high recurrence rate.
Avni T; Babitch T; Ben-Zvi H; Hijazi R; Ayada G; Atamna A; Bishara J
Int J Infect Dis; 2020 Jan; 90():237-242. PubMed ID: 31672656
[TBL] [Abstract][Full Text] [Related]
24. Clostridioides difficile infections in Alberta: The validity of administrative data using ICD-10 diagnostic codes for CDI surveillance versus clinical infection surveillance.
Pfister T; Rennert-May E; Ellison J; Bush K; Leal J
Am J Infect Control; 2020 Dec; 48(12):1431-1436. PubMed ID: 32810568
[TBL] [Abstract][Full Text] [Related]
25. An Observational Cohort Study of
Rao K; Higgins PDR; Young VB
mSphere; 2018; 3(3):. PubMed ID: 29794054
[TBL] [Abstract][Full Text] [Related]
26. Fidaxomicin for the Treatment of
Giacobbe DR; Vena A; Falcone M; Menichetti F; Bassetti M
Antibiotics (Basel); 2022 Oct; 11(10):. PubMed ID: 36290023
[TBL] [Abstract][Full Text] [Related]
27. Bezlotoxumab for Preventing Recurrent Clostridioides difficile Infection: A Narrative Review from Pathophysiology to Clinical Studies.
Giacobbe DR; Dettori S; Di Bella S; Vena A; Granata G; Luzzati R; Petrosillo N; Bassetti M
Infect Dis Ther; 2020 Sep; 9(3):481-494. PubMed ID: 32632582
[TBL] [Abstract][Full Text] [Related]
28. Healthcare burden of recurrent Clostridioides difficile infection in Japan: A retrospective database study.
Kunishima H; Ito K; Laurent T; Abe M
J Infect Chemother; 2018 Nov; 24(11):892-901. PubMed ID: 30190105
[TBL] [Abstract][Full Text] [Related]
29. Pediatric Fecal Microbiota Transplantation in Recurrent
Parnell JM; Nicholson MR; Kellermayer R; Kahn SA
Pediatr Ann; 2021 Dec; 50(12):e515-e521. PubMed ID: 34889135
[TBL] [Abstract][Full Text] [Related]
30. Safety and efficacy of fecal microbiota transplantation to treat and prevent recurrent
Ali H; Khurana S; Ma W; Peng Y; Jiang ZD; DuPont H; Zhang HC; Thomas AS; Okhuysen P; Wang Y
J Cancer; 2021; 12(21):6498-6506. PubMed ID: 34659541
[No Abstract] [Full Text] [Related]
31. Clinical burden of recurrent
Feuerstadt P; Nelson WW; Teigland C; Dahdal DN
Antimicrob Steward Healthc Epidemiol; 2022; 2(1):e60. PubMed ID: 36483433
[TBL] [Abstract][Full Text] [Related]
32. Treatment of Clostridioides difficile Infection and Non-compliance with Treatment Guidelines in Adults in 10 US Geographical Locations, 2013-2015.
Novosad SA; Mu Y; Winston LG; Johnston H; Basiliere E; Olson DM; Farley MM; Revis A; Wilson L; Perlmutter R; Holzbauer SM; Whitten T; Phipps EC; Dumyati GK; Beldavs ZG; Ocampo VLS; Davis CM; Kainer M; Gerding DN; Guh AY
J Gen Intern Med; 2020 Feb; 35(2):412-419. PubMed ID: 31768906
[TBL] [Abstract][Full Text] [Related]
33. Long-Term Efficacy and Safety of Fecal Microbiota Transplantation for Treatment of Recurrent Clostridioides difficile Infection.
Perler BK; Chen B; Phelps E; Allegretti JR; Fischer M; Ganapini V; Krajiceck E; Kumar V; Marcus J; Nativ L; Kelly CR
J Clin Gastroenterol; 2020 Sep; 54(8):701-706. PubMed ID: 32011405
[TBL] [Abstract][Full Text] [Related]
34. Analysis of C. difficile infection-related outcomes in European participants in the bezlotoxumab MODIFY I and II trials.
Bouza E; Cornely OA; Ramos-Martinez A; Plesniak R; Ellison MC; Hanson ME; Dorr MB
Eur J Clin Microbiol Infect Dis; 2020 Oct; 39(10):1933-1939. PubMed ID: 32504314
[TBL] [Abstract][Full Text] [Related]
35. Real-World Experience with Bezlotoxumab for Prevention of Recurrence of
Escudero-Sánchez R; Ruíz-Ruizgómez M; Fernández-Fradejas J; García Fernández S; Olmedo Samperio M; Cano Yuste A; Valencia Alijo A; Díaz-Pollán B; Rodríguez Hernández MJ; Merino De Lucas E; Martín Segarra O; Sáez Bejar C; Armiñanzas Castillo C; Gutiérrez Gutiérrez B; Rodríguez-Pardo D; Ramos Martínez A; De La Torre Cisneros J; López-Medrano F; Cobo Reinoso J
J Clin Med; 2020 Dec; 10(1):. PubMed ID: 33374989
[TBL] [Abstract][Full Text] [Related]
36. Characteristics and management of children with Clostridioides difficile infection at a tertiary pediatric hospital in China.
Li X; Xiao F; Li Y; Hu H; Xiao Y; Xu Q; Li D; Yu G; Wang Y; Zhang T
Braz J Infect Dis; 2022; 26(4):102380. PubMed ID: 35753395
[TBL] [Abstract][Full Text] [Related]
37. Incidence of and risk factors for recurrent Clostridioidesdifficile infection in Japan using a claims database: A retrospective cohort study.
Mikamo H; Kondo T; Okuyama K; Marcella SW; Ruzicka DJ
Anaerobe; 2020 Feb; 61():102139. PubMed ID: 31830597
[TBL] [Abstract][Full Text] [Related]
38. Faecal microbiota transplantation for recurrent
Baunwall SMD; Lee MM; Eriksen MK; Mullish BH; Marchesi JR; Dahlerup JF; Hvas CL
EClinicalMedicine; 2020 Dec; 29-30():100642. PubMed ID: 33437951
[TBL] [Abstract][Full Text] [Related]
39. Characterization and risk factors for recurrence of Clostridioides (Clostridium) difficile infection in Japan: A nationwide real-world analysis using a large hospital-based administrative dataset.
Kimura T; Snijder R; Sugitani T
J Infect Chemother; 2019 Aug; 25(8):615-620. PubMed ID: 30987950
[TBL] [Abstract][Full Text] [Related]
40. Fecal Microbiota Transplant Decreases Mortality in Patients with Refractory Severe or Fulminant Clostridioides difficile Infection.
Cheng YW; Phelps E; Nemes S; Rogers N; Sagi S; Bohm M; El-Halabi M; Allegretti JR; Kassam Z; Xu H; Fischer M
Clin Gastroenterol Hepatol; 2020 Sep; 18(10):2234-2243.e1. PubMed ID: 31923639
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
